The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
Official Title: A PHASE 2, OPEN-LABEL, TWO ARM TRIAL TO EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS WITH ADVANCED NSCLC AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN AND FAILURE OF PRIOR TREATMENT WITH ERLOTINIB
Study ID: NCT00548093
Brief Summary: To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope, Duarte, California, United States
City of Hope Medical Group, Pasadena, California, United States
City of Hope South Pasadena Cancer Center, South Pasadena, California, United States
Rocky Mountain Lions Eye Institute, Aurora, Colorado, United States
University of Colorado Hospital, Anschutz Cancer Pavilion, Aurora, Colorado, United States
University of Colorado Hospital, Anschutz Inpatient Pavilion, Aurora, Colorado, United States
University of Colorado Hospital, Aurora, Colorado, United States
Grady Health Systems, Atlanta, Georgia, United States
Emery University Hospital Midtown, Atlanta, Georgia, United States
Emory Clinic, Atlanta, Georgia, United States
Emory University Hospital, Atlanta, Georgia, United States
Winship Cancer Institute, Atlanta, Georgia, United States
CCR, National Cancer Institute, Bethesda, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
Lawrence and Idell Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR